Breakthrough! China's First-In-Class PB2-Targeting Antiviral Onradivir Tablets Approved for Market Launch, Pioneering New Era in Influenza Treatment!

May 22, 2025 – China's National Medical Products Administration (NMPA) has officially approved Onradivir tablets (brand name: ANRUIWEI®), a Class 1 innovative drug developed by Guangdong Raynovent Biotech Co., Ltd. ("Raynovent"), for the treatment of uncomplicated influenza A in adults. The recommended dosage is 0.6g (3 tablets) once daily for 5 consecutive days.

As the world's first anti-influenza drug targeting the PB2 subunit of influenza A virus RNA polymerase, Onradivir offers rapid, potent, and low-resistance antiviral activity, providing a novel "Made-in-China" solution for global influenza prevention and control.